ELACESTRANT (ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER) VERSUS STANDARD ENDOCRINE THERAPY FOR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER: RESULTS FROM THE RANDOMIZED PHASE III EMERALD TRIAL.

RIPRETINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOURS (INVICTUS): A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL

EVENT-FREE SURVIVAL BY RESIDUAL CANCER BURDEN WITH PEMBROLIZUMAB IN EARLY-STAGE TRIPLE NEGATIVE BREAST CANCER (TNBC): EXPLORATORY ANALYSIS FROM KEYNOTE-522